In this video, Rebecca Stone, MD, MS, discussed the need for improved prevention and screening methods for ovarian cancer.

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) March 4 (Reuters) - Adding a minimally invasive laser procedure to ...